Frankfurt - Delayed Quote EUR
Intellia Therapeutics, Inc. (38I.F)
6.98
+0.28
+(4.18%)
At close: 3:49:30 PM GMT+2
Research Analysis
Earnings Estimate
| Currency in USD | Current Qtr. (Mar 2025) | Next Qtr. (Jun 2025) | Current Year (2025) | Next Year (2026) |
|---|---|---|---|---|
| No. of Analysts | -- | -- | -- | -- |
| Avg. Estimate | 0 | 0 | 0 | 0 |
| Low Estimate | 0 | 0 | 0 | 0 |
| High Estimate | 0 | 0 | 0 | 0 |
| Year Ago EPS | -- | -- | -- | -- |
Revenue Estimate
| Currency in USD | Current Qtr. (Mar 2025) | Next Qtr. (Jun 2025) | Current Year (2025) | Next Year (2026) |
|---|---|---|---|---|
| No. of Analysts | 19 | 19 | 27 | 25 |
| Avg. Estimate | 11.99M | 11.97M | 49.27M | 43.61M |
| Low Estimate | -- | -- | -- | -- |
| High Estimate | 50M | 50M | 210M | 100M |
| Year Ago Sales | 28.93M | 6.96M | 57.88M | 49.27M |
| Sales Growth (year/est) | -58.58% | 72.02% | -14.88% | -11.48% |
EPS Trend
| Currency in USD | Current Qtr. (Mar 2025) | Next Qtr. (Jun 2025) | Current Year (2025) | Next Year (2026) |
|---|---|---|---|---|
| Current Estimate | 0 | 0 | 0 | 0 |
| 7 Days Ago | 0 | 0 | 0 | 0 |
| 30 Days Ago | 0 | 0 | 0 | 0 |
| 60 Days Ago | 0 | 0 | 0 | 0 |
| 90 Days Ago | 0 | 0 | 0 | 0 |
EPS Revisions
| Currency in USD | Current Qtr. (Mar 2025) | Next Qtr. (Jun 2025) | Current Year (2025) | Next Year (2026) |
|---|---|---|---|---|
| Up Last 7 Days | -- | -- | -- | -- |
| Up Last 30 Days | -- | -- | -- | -- |
| Down Last 7 Days | -- | -- | -- | -- |
| Down Last 30 Days | -- | -- | -- | -- |
Growth Estimates
| Current Qtr. | Next Qtr. | Current Year | Next Year | |
|---|---|---|---|---|
| 38I.F | -- | -- | -- | -- |
| S&P 500 | 6.94% | 4.52% | 8.32% | 14.18% |
Upgrades & Downgrades
| Upgrade | Wolfe Research: Peer Perform to Outperform | 4/21/2025 |
| Initiated | HC Wainwright & Co.: Buy | 3/5/2025 |
| Maintains | Truist Securities: Buy to Buy | 3/4/2025 |
| Maintains | Barclays: Overweight to Overweight | 2/28/2025 |
| Maintains | Citigroup: Neutral to Neutral | 2/28/2025 |
| Maintains | Wells Fargo: Overweight to Overweight | 2/28/2025 |
Related Tickers
05Y.F Vivoryon Therapeutics N.V.
1.8120
-2.16%
F6T.F Fate Therapeutics, Inc.
1.1715
+2.14%
22UA.F BioNTech SE
87.65
-13.39%
GRCE Grace Therapeutics, Inc.
2.4900
+4.62%
DYN Dyne Therapeutics, Inc.
11.06
-0.45%
TPST Tempest Therapeutics, Inc.
7.76
-3.60%
OCGN Ocugen, Inc.
0.7192
-2.40%
CRSP CRISPR Therapeutics AG
38.27
-2.15%